Rationale: Although the outcome of sepsis benefits from the prompt administration of appropriate antibiotics on correct diagnosis, the assessment of infection in critically ill patients is often a challenge for clinicians. In this setting, simple biomarkers, especially when used in combination, could prove useful. Objectives: To determine the usefulness of combination biomarkers to diagnose sepsis. Methods: Three hundred consecutive patients were enrolled to construct a biologic score that was next validated in an independent prospective cohort of 79 critically ill patients from another center. Measurement and Main Results: Plasma concentrations of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and procalcitonin (PCT) were assayed, and the expression of the high-affinity immunoglobulin-Fc fragment receptor I (FcgRI) CD64 on neutrophils (polymorphonuclear [PMN] CD64 index) in flow cytometry was measured. A "bioscore" combining these biomarkers was constructed. Serum concentrations of PCT and sTREM-1 and the PMN CD64 index were higher in patients with sepsis compared with all others (P , 0.001 for the three markers). These biomarkers were all independent predictors of infection, the best receiver-operating characteristic curve being obtained for the PMN CD64 index. The performance of the bioscore, better than that of each individual biomarker, was externally confirmed in the validation cohort. Conclusions: This prospective study, including inceptive and validation cohorts of unselected intensive care unit patients, demonstrates the high performance of a bioscore combining the PMN CD64 index together with PCT and sTREM-1 serum levels in diagnosing sepsis in the critically ill patient.
Among critically ill patients admitted to intensive care units (ICU), at least one-third to half of them is ultimately diagnosed with sepsis, which is a leading cause of mortality and morbidity (1) . The outcome of sepsis has been shown to benefit from the prompt administration of appropriate antibiotics on correct diagnosis (2) . This latter issue is critical to limit the selection of antibioresistant bacterial species, whereas early recognition of sepsis remains a matter of concern given the low diagnostic accuracy of such usual tools as clinical signs, fever, or elevated white blood cell counts (3, 4) . In this context, the development of new biomarkers is desirable. Among the most recent ones, cumulative published evidence supports the use of procalcitonin (PCT) measurement. The soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and the intensity of expression of the high-affinity immunoglobulin-Fc fragment receptor I (FcgRI) CD64 on polymorphonuclear (PMN) cells are also of potential interest (3, (5) (6) (7) (8) (9) . Indeed, several studies have suggested the usefulness of these markers in the early stages of sepsis, before a positive microbiologic identification can be obtained. However several limitations should be mentioned. PCT elevation also occurs in nonseptic inflammatory states, such as postoperative conditions, resuscitated cardiac arrest, or cardiogenic shock. In addition, low PCT levels may be seen in patients with localized infections or early sepsis (10) . Although less published data exist regarding sTREM-1, a recent metaanalysis concluded that it was of clinical interest (8) . It is, however, worth noting that it may lack specificity because sTREM-1 elevation has been observed during noninfectious lung injury conditions, such as trauma or aspiration (11, 12) . Additional markers are therefore required to improve PCT diagnosis accuracy.
The increased expression level of CD64 on PMN, indicative of these cells' activation, was published as highly indicative of sepsis in small cohorts (13) (14) (15) (16) (17) . Although promising, these findings should be validated in larger studies including adults. Moreover, in contrast to previous biomarkers, the specificity and sensitivity of the assay of CD64 expression by PMN measurement has to be better assessed. Altogether, these data suggest that given their respective predictive values, a diagnosis approach seldom used (18, 19) combining these three biomarkers could improve sepsis recognition.
Here we performed a systematic study aimed at evaluating the individual and combined diagnostic accuracy of PCT, sTREM-1, and CD64 expression on PMN for the differential diagnosis of sepsis in critically ill patients at ICU admission. In a derivation cohort 300 consecutive patients were enrolled to construct a simple biologic score combining the three biomarkers and was next validated in an independent prospective cohort of 79 critically ill patients from another center.
METHODS

Study Population
All consecutive patients newly hospitalized in the ICU of the University Hospital of Nancy, France, were prospectively enrolled in the study, except those admitted on weekends. There were no exclusion criteria. These 300 patients constituted the inception cohort, which was used to determine the performance of the parameters examined in this study.
A distinct population of 79 patients was prospectively recruited in the ICU of the University Hospital of Dijon, France, with the same criteria and during a 4-month period. This population constituted the validation cohort.
Approval of the institutional review board and informed consent were obtained before inclusion.
Data Collection
On admission to the ICU, the following items were recorded for each patient: age, sex, severity of underlying medical condition stratified according to the criteria of McCabe and Jackson, Simplified Acute Physiology Score II (20) , Sepsis-related Organ Failure Assessment score (21) , and reason for admission into the ICU. The following baseline variables were also recorded at inclusion: body temperature, leukocyte count, presence of shock, and use of previous antimicrobial therapy. The length of ICU stay and ICU mortality were also recorded.
When infection at admission was suspected by the attending physician, microbiologic tests and antimicrobial therapy were prescribed according to the usual practice of the ICU without interference by the research team or the knowledge of biomarker measurement results. Two intensivists retrospectively reviewed all medical records pertaining to each patient and independently classified the diagnosis as no infection, sepsis, severe sepsis, or septic shock at the time of admission, according to established consensus definitions (4) . Agreement concerning the diagnosis was achieved in all cases. Both intensivists were masked to the results of the biomarkers studied.
Measurements of PCT, sTREM-1, and PMN CD64 Index Within 12 hours after admission blood samples were drawn to assay PCT and sTREM-1 and to evaluate CD64 expression on PMN. Sampling was repeated on Day 2. PCT concentrations were measured in a serum sample, using an immunoassay with a sandwich technique and a chemiluminescent detection system (LumiTest; Brahms Diagnostica, Berlin, Germany). Serum concentrations of soluble TREM-1 were measured in duplicate by sandwich ELISA using the Quantikine kit assay (R&D Systems, Minneapolis, MN). Interassay and intraassay coefficients of variation were lower than 7%. The expression of CD64 on neutrophils was measured by quantitative flow cytometry within 12 hours after blood sampling using the Leuko64 assay (Trillium Diagnostics, LLC, Brewer, ME) as previously described (13) (14) (15) (16) (17) .
Statistical Analyses
Descriptive results of continuous variables were expressed as mean (6 SD) or median (interquartile range) depending of the normality of their distribution. Variables were tested for their association with the diagnosis using Pearson chi-square test for categorical data and Mann-Whitney U test for numerical data. Receiver-operating characteristic (ROC) curves were constructed to illustrate cut-off values of PCT, sTREM-1, and PMN CD64 index. Biomarker values were transformed into quartiles based on their distribution and their accuracy to diagnose sepsis was evaluated using a multiple stepwise logistic regression model. Any covariate with univariate significance of P less than 0.10 was eligible for inclusion in the model. Having determined that these biomarkers were independently associated with the diagnosis, we generated a scoring system or "bioscore" attributing one point per biomarker with a value above the optimal cut-off point. This bioscore was next tested for its association with diagnosis through logistic regression analysis and calibration of the model performed through Hosmer-Lemeshow testing.
The modeling process was performed on the inception cohort of patients and applied then to the validation cohort.
RESULTS
Characteristics of the Inception Cohort Patients
The baseline characteristics of the inception cohort are shown in Table 1 . Among the 300 patients enrolled in this study, 154 (51.3%) were diagnosed with sepsis. The source of infection and microorganisms involved are shown in Table E1 in the online supplement. At admission, PCT, sTREM-1, and PMN CD64 index were higher in patients with sepsis compared with all others (P , 0.001 for the three markers) ( Table 1 ; see Figure  E1 ). Among patients with sepsis, PCT and sTREM-1 concentrations were higher in case of gram-negative as compared with gram-positive infections, respectively 30.09 (4.55-76.01) versus 1.33 (1.04-4.98) ng/ml for PCT, and 943 (518-1339) versus 676 (390-1,010) pg/ml for sTREM-1 (P , 0.0001 for both).
Accuracy of Baseline PCT, sTREM-1, and PMN CD4 Index in Diagnosing Sepsis
As shown in Figure 1 Table 2 summarizes the performances of each of these biomarkers in diagnosing sepsis. PMN CD64 index proved to be the best individual marker in terms of specificity (95.2%) and sensitivity (84.4%).
In multiple logistic regression, PCT, sTREM-1, and PMN CD64 index were all found to be independent predictors of sepsis (Table 3) .
Combination of PCT, sTREM-1, and PMN CD64 Index in a Bioscore
To determine whether the combination of these three biomarkers into a single score could improve the diagnostic performance, individual data were scored as 0 or 1 whether they were below or above the threshold previously determined with the ROC curves as shown in Table 2 . This constituted the bioscore, which therefore ranged between 0 (all three markers below their respective thresholds) and 3 (all three markers above threshold). We chose to not weigh individual biomarkers based on their respective Wald coefficients (Table 3) because results did not differ from those presented below, and from a clinical standpoint the simplest tests are likely to be the most applicable.
The probability of sepsis increased together with the bioscore with rates of infection of 3.8% for a bioscore of 0-100% for a bioscore of 3 ( Figure 2 ).
When the bioscore was entered into the multiple logistic regression model (Table 3) its performance was shown to be far better than that of each individual biomarker taken individually. The Hosmer-Lemeshow goodness-of-fit test showed that the model was well calibrated with P equal to 0.74. The AUC was 0.97 (95% CI, 0.95-0.99) and 90.9% of patients were correctly classified by use of the model.
When one of the biomarkers was omitted from the bioscore (this score thus ranging from 0-2), diagnostic performances were modified. The best odds ratio was observed for the combination PMN CD64 index plus sTREM-1 at 26.50 (95% CI, 13.47-52.14), followed by PMN CD64 index plus PCT at 18.16 (95% CI, 10.15-32.50), and sTREM-1 plus PCT at 11.48 (95% CI, 6.80-19.38).
To further test the performance of the bioscore on sepsis prediction for clinical relevance, the entire inception cohort of 300 patients was classified according to baseline bioscore. A bioscore of 0 (35% of patients) excluded the presence of sepsis for all but 4 of the 105 patients (96.2%) in this category (two suffering from herpes simplex virus-1 encephalitis, and two with a mild acute exacerbation of chronic obstructive pulmonary disease). By contrast, all but 5 of the 134 patients (96.3%) with a bioscore of 2 or 3 (44.6% of the cohort) were septic. Between these two groups, the 61 patients with a bioscore of 1 (20.3% of the cohort) were balanced between infected (34.4%) and not infected (65.6%) (Figure 3) .
Recalculation of the bioscore for these 61 patients with a score of 1, using values obtained 24 hours after admission, showed improved data with 26.2% of the patients down to 0 and absence of sepsis, and 14.8% with a bioscore increased up to 2 or 3 and the presence of sepsis. For the 36 patients (59%) who did not change and remained with a bioscore of 1 the sepsis rate still was 33.3%. Thus, from a clinical point of view, the bioscore was overall useful in 88% of patients over the first 24 hours after admission.
Usefulness of PCT, sTREM-1, PMN CD64 Index, and Bioscore among Patients with an Initial Suspicion of Infection
We next evaluated the usefulness of the three biomarkers and the bioscore among the 228 patients presenting with a clinical suspicion of infection. All of them initially received antibiotics.
Performances of individual or combined markers were very close to those obtained in the entire cohort of patients (see Tables E2  and E3 , and Figure E2 ). Interestingly, the optimal cut-offs as determined from ROC curves were similar to those derived from the entire population (see Table E2 ).
External Validation of the Bioscore
The characteristics of the 79 patients included in the validation cohort are presented in Table E4 . Compared with patients enrolled in the inception cohort, they were older, more often immunosuppressed, received more antibiotics before ICU admission, and required vasopressors more frequently. Among these 79 patients, 36 (45.6%) were diagnosed with sepsis. The characteristics of patients with and without sepsis are shown in Table E5 . In logistic regression analysis, the diagnostic odds ratios of the baseline bioscore in this smaller cohort was close to that for the inception cohort (Table 4) . A similar usefulness of the bioscore at baseline and on Day 1 was observed (see Figure E3) , with a definitive diagnosis ultimately predicted for 86.1% of the patients over the first 24 hours.
In this validation cohort, the bioscore also performed well in the subgroup of patients with a clinical suspicion of infection (n ¼ 40). Respective odds ratios were 3.3 (95% CI, 1.3-40.2), 40 (2-794.5), and 90 (4.7-1,709) for bioscore 1, 2, and 3 (all P , 0.05).
DISCUSSION
This study reports, in two independent cohorts of patients, a prospective evaluation of the diagnostic value of three sepsis biomarkers considered respectively as individual parameters or as a combined bioscore. We show here that PCT, sTREM-1, and PMN CD64 index were useful to diagnose sepsis, the best being assessment of CD64 expression on PMNs. We then combined these markers in a simple score, called "bioscore," which turned out to be associated with an impressive diagnostic accuracy and proved really useful from a clinical standpoint in rapidly assigning more than 80% of the patients to having or not having sepsis. PCT has proved useful for the diagnosis of sepsis in critically ill patients, although it may lack specificity as attested by the high rate of elevated PCT in clinical conditions unrelated to sepsis (5) (6) (7) (22) (23) (24) . Accordingly, several studies have provided less convincing data making controversial the use of this biomarker (25, 26) . Here, we observed satisfactorily discriminating sensitivity and specificity values reaching 83% and 84%, respectively.
By contrast, sTREM-1 showed a diagnostic accuracy lower than expected in both these cohorts. Our group and others have reported that the test was sensitive and specific in the ICU setting (8, 27) . The sensitivity of the assay was poorer here, possibly explained by a lower prevalence of infection than in published reports. Nevertheless, the performance of the bioscore decreased when this marker was omitted, and the best odds ratio was observed for the combination PMN CD64 index plus sTREM-1.
CD64 expression up-regulation on the cell surface of PMN and monocytes is considered to be a very early step of the immune host response to bacterial infection (28) . Conversely, CD64 expression seems unchanged in patients with inflammatory states from noninfectious origin, especially on neutrophils (16) . Accordingly, previously published clinical data have suggested the high diagnostic value of the PMN CD64 index measurement (13) (14) (15) (29) (30) (31) . However, these were small series of patients including mainly pediatric subjects. In a recently published work performed in an ICU the CD64 index was found to have a lower sensitivity (63%) for the CD64 index than previously reported, although its specificity was excellent (32) . Our findings are also in contradiction with this study. This may be explained by the fact that Gros and coworkers (32) only included patients with a documented infection, thus missing many infected patients without microbial documentation, leading to a higher CD64 cutoff. The second explanation may be technical: although using the same commercial kit than in our study, Gros and coworkers (32) measured CD64 index "within 36 hours" after blood sampling rather than within 12 hours. This may have led to a progressive decrease of CD64 expression and a high number of false-negative patients. Despite these small discrepancies, the PMN CD64 index was confirmed here to be the most performing parameter. In addition, our work illustrates the high feasibility of the CD64 index measurement in daily practice. The test is performed as an individual parameter, and can be realized at any time, provided a flow cytometry facility is available. It is a whole-blood lysis no-wash approach unlikely to artifactually modify any of the intrinsic parameters of the cells tested through the analytic pathway.
Beyond the individual performance of each biomarker, their combination within a bioscore additionally seemed to be a pragmatic and efficient way to differentiate between ICU patients with and without sepsis. Therefore, with at least two of the three markers above their respective threshold (bioscore 2 or 3) at baseline, more than 90% of patients were found to be infected.
After the clinical work-up is achieved, and before getting microbiologic data, the diagnosis of sepsis remains in many cases a plausible yet not demonstrated option. With one single biomarker, incertitude often remains and the best therapeutic schedule is difficult to establish, keeping in mind the consequences of unnecessary antibiotherapy. Some authors have proposed to combine biomarkers to improve the diagnostic accuracy individually provided by each one (19, 33) . The pragmatic approach applied here relies on a simple bedside bioscore of 0-3, with a strong positive predictive value for infection if above 1. This threshold is reliable at baseline for scores 0, 2, and 3, and reinforced by Day 1 data for most patients with a baseline bioscore of 1. Although the bioscore's calculation implies the measurement of three biomarkers, it clearly provides relevant information likely to strengthen the physician's decision in addition to clinical work-up.
This study is especially interesting because consecutive ICU patients were enrolled, therefore without necessarily a clinical suspicion of sepsis. This had the clear advantage of not using healthy subjects as controls subjects, but to place the tests in the "real life" conditions of the ICU. It may be argued that for some of these patients, the dilemma of "sepsis or not sepsis" did not exist and that in routine conditions the indication for prescribing either test or the entire bioscore could be more limited, and this can be accepted. Nevertheless, when analyses were restricted only to patients presenting with a clinical suspicion of sepsis, performances of the biomarkers and the bioscore seemed to be very close to those obtained in the entire cohort of patients. Such an absence of selection criteria may also explain the higher thresholds established for all three parameters studied than previously reported.
The combination of several biomarkers to improve diagnosis or predict outcome is used in various disorders, such as liver fibrosis, breast cancer, and cardiovascular diseases (34) (35) (36) , although this strategy has not yet been validated for sepsis. The biologic scoring system we propose here implies the measurement of three different markers. At first glance, this raises feasibility issues. Indeed, if PCT measurement may be performed easily, sTREM-1 determination requires an ELISA assay whereas CD64 assessment requires access to a flow cytometer. These facilities may not be routinely available in all hospitals. This may constitute an obstacle to the widespread use of such a strategy, although point-of-care technologies are rapidly spreading.
Finally, the scoring strategy we propose must be evaluated through medicoeconomic studies that should balance the weight of useless antibiotic therapies toward unacceptable delays in the administration of appropriate antimicrobial agents in any patient with actual but unconfirmed sepsis.
In conclusion, this prospective, two-part study, including inceptive and validation cohorts of unselected ICU patients in two different settings strengthens the high diagnostic value of the PMN CD64 index, and the even higher value of a bioscore combining this parameter with PCT and sTREM-1 serum levels. Whether any of these should routinely be implemented in ICUs, and on which screening criteria, remains to be established by consensus confrontations. This work, however, provides robust thresholds for all three parameters as a strong basis for further multicenter studies.
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